Literature DB >> 1961358

Disruption of classical conditioning in patients with Alzheimer's disease.

P R Solomon1, E Levine, T Bein, W W Pendlebury.   

Abstract

One of the primary features of Alzheimer's disease (AD) is a disorder of memory. Although considerable effort has been devoted to characterizing this memory disorder, simple forms of memory such as classical (Pavlovian) conditioning have not been studied. The prevailing view has been that these simple forms of memory are not affected in AD. These forms of memory, however, may be of particular interest because they are beginning to be well understood at the neurobiological level. Because of this, when memory disorders are detected, it may be possible to specify their neurobiological substrate. We now report that classical conditioning of the eyeblink response is disrupted in AD patients compared to age-matched controls. This deficit in conditioning is not due to nonassociative factors such as changes in sensitivity to stimuli or disruption of the motor response. The results are considered in terms of using simple forms of memory to help generate hypotheses regarding the neurobiology of age-related memory disorders.

Entities:  

Mesh:

Year:  1991        PMID: 1961358     DOI: 10.1016/0197-4580(91)90004-4

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  15 in total

1.  The M1 muscarinic agonist CI-1017 facilitates trace eyeblink conditioning in aging rabbits and increases the excitability of CA1 pyramidal neurons.

Authors:  C Weiss; A R Preston; M M Oh; R D Schwarz; D Welty; J F Disterhoft
Journal:  J Neurosci       Date:  2000-01-15       Impact factor: 6.167

2.  Cholinergic septo-hippocampal innervation is required for trace eyeblink classical conditioning.

Authors:  Angela Fontán-Lozano; Julieta Troncoso; Alejandro Múnera; Angel Manuel Carrión; José María Delgado-García
Journal:  Learn Mem       Date:  2005-11-14       Impact factor: 2.460

3.  Functional mapping of human learning: a positron emission tomography activation study of eyeblink conditioning.

Authors:  T A Blaxton; T A Zeffiro; J D Gabrieli; S Y Bookheimer; M C Carrillo; W H Theodore; J F Disterhoft
Journal:  J Neurosci       Date:  1996-06-15       Impact factor: 6.167

4.  The effects of scopolamine, lorazepam, and glycopyrrolate on classical conditioning of the human eyeblink response.

Authors:  M Bahro; B G Schreurs; T Sunderland; S E Molchan
Journal:  Psychopharmacology (Berl)       Date:  1995-12       Impact factor: 4.530

Review 5.  Eyeblink classical conditioning differentiates normal aging from Alzheimer's disease.

Authors:  D S Woodruff-Pak
Journal:  Integr Physiol Behav Sci       Date:  2001 Apr-Jun

6.  A functional anatomical study of associative learning in humans.

Authors:  S E Molchan; T Sunderland; A R McIntosh; P Herscovitch; B G Schreurs
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-16       Impact factor: 11.205

7.  Studies of aluminum neurobehavioral toxicity in the intact mammal.

Authors:  R A Yokel; D D Allen; J J Meyer
Journal:  Cell Mol Neurobiol       Date:  1994-12       Impact factor: 5.046

8.  Age-related impairment in the 250-millisecond delay eyeblink classical conditioning procedure in C57BL/6 mice.

Authors:  Richard W Vogel; Michael Ewers; Charlene Ross; Thomas J Gould; Diana S Woodruff-Pak
Journal:  Learn Mem       Date:  2002 Sep-Oct       Impact factor: 2.460

9.  Small molecule p75NTR ligands reduce pathological phosphorylation and misfolding of tau, inflammatory changes, cholinergic degeneration, and cognitive deficits in AβPP(L/S) transgenic mice.

Authors:  Thuy-Vi V Nguyen; Lin Shen; Lilith Vander Griend; Lisa N Quach; Nadia P Belichenko; Nay Saw; Tao Yang; Mehrdad Shamloo; Tony Wyss-Coray; Stephen M Massa; Frank M Longo
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

10.  Nefiracetam (DM-9384): effect on eyeblink classical conditioning in older rabbits.

Authors:  D S Woodruff-Pak; Y T Li
Journal:  Psychopharmacology (Berl)       Date:  1994-03       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.